Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmonary Arterial Hypertension - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension - The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects - The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Pulmonary Arterial Hypertension Overview 9 Therapeutics Development 10 Pipeline Products for Pulmonary Arterial Hypertension - Overview 10 Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 11 Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 12 Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 15 Pulmonary Arterial Hypertension - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pulmonary Arterial Hypertension - Products under Development by Companies 19 Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 23 Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 24 Actelion Ltd 24 APT Therapeutics, Inc. 25 Arena Pharmaceuticals, Inc. 26 Ascendis Pharma A/S 27 AVEO Pharmaceuticals, Inc. 28 Bial - Portela & Ca, S.A. 29 Celsion Corporation 30 Celtaxsys, Inc. 31 Chugai Pharmaceutical Co., Ltd. 32 Complexa, Inc. 33 Eli Lilly and Company 34 Galectin Therapeutics, Inc. 35 Gilead Sciences, Inc. 36 Hanmi Pharmaceuticals, Co. Ltd. 37 HitGen LTD 38 Insmed Incorporated 39 INVENT Pharmaceuticals, Inc. 40 Johnson & Johnson 41 Kowa Company, Ltd. 42 Mast Therapeutics, Inc. 43 Mezzion Pharma Co. Ltd. 44 miRagen Therapeutics, Inc. 45 Morphogen-IX Limited 46 Nippon Kayaku Co., Ltd. 47 Nippon Shinyaku Co., Ltd. 48 Novartis AG 49 Peloton Therapeutics, Inc. 50 PhaseBio Pharmaceuticals, Inc. 51 Pluristem Therapeutics Inc. 52 Proteo, Inc. 53 Pulmokine, Inc. 54 Reata Pharmaceuticals, Inc. 55 Respira Therapeutics, Inc. 56 Reviva Pharmaceuticals Inc. 57 Selten Pharma, Inc 58 Silence Therapeutics Plc 59 SteadyMed Therapeutics, Inc. 60 Suda Ltd 61 Toray Industries, Inc. 62 Pulmonary Arterial Hypertension - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Target 64 Assessment by Mechanism of Action 68 Assessment by Route of Administration 72 Assessment by Molecule Type 74 Drug Profiles 76 acebilustat - Drug Profile 76 Antibody for Pulmonary Arterial Hypertension - Drug Profile 79 Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 80 APT-602 - Drug Profile 81 AV-353 - Drug Profile 82 bardoxolone methyl - Drug Profile 83 beraprost sodium ER - Drug Profile 87 beraprost sodium SR - Drug Profile 88 BIA-51058 - Drug Profile 89 BMP-10 - Drug Profile 90 BMP-9 - Drug Profile 91 CTX-3397 - Drug Profile 92 CXA-10 - Drug Profile 93 Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 95 GMA-301 - Drug Profile 96 GMCT-01 - Drug Profile 97 GRMD-02 - Drug Profile 101 HGP-1207 - Drug Profile 112 INS-1009 - Drug Profile 113 INV-240 - Drug Profile 115 JNJ-26993135 - Drug Profile 116 KAR-5585 - Drug Profile 117 macitentan - Drug Profile 118 MFC-1040 - Drug Profile 123 MFC-2040 - Drug Profile 124 Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 125 Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 126 PB-1046 - Drug Profile 127 PB-1120 - Drug Profile 129 PF-543 - Drug Profile 130 pitavastatin NP - Drug Profile 131 PK-10453 - Drug Profile 132 PK-10571 - Drug Profile 133 PLX-PAD - Drug Profile 134 PT-2977 - Drug Profile 142 QCC-374 - Drug Profile 143 R-190 - Drug Profile 144 ralinepag - Drug Profile 146 RP-5063 - Drug Profile 148 RT-234 - Drug Profile 150 selexipag - Drug Profile 151 selonsertib - Drug Profile 155 sirolimus albumin-bound - Drug Profile 156 Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158 Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 159 Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 160 Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 161 Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 162 sodium nitrite - Drug Profile 163 SPI-054 - Drug Profile 166 SPI-183 - Drug Profile 167 SUD-004 - Drug Profile 168 Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 169 tacrolimus - Drug Profile 170 tadalafil - Drug Profile 171 tiprelestat - Drug Profile 173 tocilizumab - Drug Profile 177 TR-422 - Drug Profile 185 treprostinil - Drug Profile 186 treprostinil diolamine - Drug Profile 187 ubenimex - Drug Profile 189 udenafil - Drug Profile 191 Pulmonary Arterial Hypertension - Dormant Projects 194 Pulmonary Arterial Hypertension - Discontinued Products 198 Pulmonary Arterial Hypertension - Product Development Milestones 199 Featured News & Press Releases 199 Appendix 209 Methodology 209 Coverage 209 Secondary Research 209 Primary Research 209 Expert Panel Validation 209 Contact Us 209 Disclaimer 210
List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016 14 Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Development by Companies, H2 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Development by Companies, H2 2016 (Contd..3) 26 Products under Investigation by Universities/Institutes, H2 2016 27 Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2016 28 Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2016 29 Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 30 Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 31 Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 32 Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2016 33 Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2016 34 Pulmonary Arterial Hypertension - Pipeline by Celtaxsys, Inc., H2 2016 35 Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 36 Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H2 2016 37 Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2016 38 Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016 39 Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2016 40 Pulmonary Arterial Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 41 Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2016 42 Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2016 43 Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 44 Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2016 45 Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 46 Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2016 47 Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 48 Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2016 49 Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H2 2016 50 Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2016 51 Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 52 Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2016 53 Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2016 54 Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 55 Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2016 56 Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2016 57 Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2016 58 Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 59 Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2016 60 Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 61 Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H2 2016 62 Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 63 Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2016 64 Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2016 65 Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2016 66 Assessment by Monotherapy Products, H2 2016 67 Number of Products by Stage and Target, H2 2016 69 Number of Products by Stage and Mechanism of Action, H2 2016 73 Number of Products by Stage and Route of Administration, H2 2016 77 Number of Products by Stage and Molecule Type, H2 2016 79 Pulmonary Arterial Hypertension - Dormant Projects, H2 2016 198 Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2016 199 Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H2 2016 200 Pulmonary Arterial Hypertension - Dormant Projects (Contd..3), H2 2016 201 Pulmonary Arterial Hypertension - Discontinued Products, H2 2016 202
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
